Angiodynamics Inc. (ANGO)
AngioDynamics Stock Up on Q1 Earnings Beat, Y/Y Pro-Forma Sales Rise
AngioDynamics (ANGO) delivers decent top-line results on a pro-forma basis in first-quarter fiscal 2025, driven by strength in the Med Tech business.
Here's Why You Should Add AngioDynamics Stock to Your Portfolio
ANGO shows growth potential with its NanoKnife system and expanding U.S. sales but faces challenges from pricing pressure and macroeconomic factors.
Why AngioDynamics Stock Is Crashing Today
Investors didn't like the medical technology company's fiscal 2025 Q1 update.
AngioDynamics, Ingevity, Levi Strauss And Other Big Stocks Moving Lower On Thursday
U.S. stocks were mostly lower, with the Dow Jones index falling around 300 points on Thursday.
AngioDynamics (ANGO) Reports Q1 Loss, Misses Revenue Estimates
AngioDynamics (ANGO) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.12 per share a year ago.
Top Wall Street Forecasters Revamp AngioDynamics Price Expectations Ahead Of Q1 Earnings
AngioDynamics, Inc. ANGO will release earnings results for its first quarter, before the opening bell on Thursday, Oct. 3.
New Strong Buy Stocks for September 30th
MRX, ANGO, OPRA, ATAT and PAM have been added to the Zacks Rank #1 (Strong Buy) List on September 30, 2024.
ANGO Initiates RECOVER-AV Trial for AlphaVac F1885 in Europe
AngioDynamics' RECOVER-AV trial evaluates the AlphaVac F1885 System's safety and efficacy in treating acute pulmonary embolism in Europe.
New Strong Buy Stocks for September 13th
ARCT, MHO, FMBH, PAM and ANGO have been added to the Zacks Rank #1 (Strong Buy) List on September 13, 2024.
AngioDynamics Stock Falls Despite CE Mark for Auryon System
ANGO's Auryon Atherectomy System earns CE Mark, which expands its European market reach and enhances PAD treatment with advanced laser technology.
AngioDynamics (ANGO) Upgraded to Strong Buy: Here's Why
AngioDynamics (ANGO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Does AngioDynamics (ANGO) Have the Potential to Rally 77.03% as Wall Street Analysts Expect?
The mean of analysts' price targets for AngioDynamics (ANGO) points to a 77% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
